Adalvo Expands Biosimilars Portfolio Through Acquisition of Romiplostim Biosimilar Program from Enzene

Start
Adalvo announced on October 27, 2026 that it acquired Enzene’s romiplostim biosimilar program. The program references Amgen’s NPLATE®, which is indicated to treat adult and chronic pediatric immune thrombocytopenia (ITP)….
By: Goodwin
Previous Story

Preserve Before You Offboard: Mobile Data and the Departing Employee

Next Story

Adalvo Expands Biosimilars Portfolio Through Acquisition of Romiplostim Biosimilar Program from Enzene